msX™ cfDNA Capture Platform

About BioCaptiva

BioCaptiva is an early-stage diagnostics company developing a novel polymer-based platform, msX™, for the direct capture and stabilization of cfDNA from liquid biopsy samples. The technology addresses key limitations in current liquid biopsy workflows, such as restricted sample volumes, poor sample quality, and complex pre-analytical processing, by enabling high-yield, selective capture from diverse biofluids with room-temperature stability. Backed by a seasoned leadership team with experience in medical devices and biotech, the company is positioning its platform to expand the utility of liquid biopsy in cancer diagnosis, monitoring, and personalized treatment planning. BioCaptiva is currently pre-revenue, focusing on technology development and commercial partnerships.

Therapeutic Areas